Search This Blog

Friday, October 2, 2026

Biogen reports 52-week Phase 2 continued efficacy, consistent safety for lupus

 

Biogen reports 52-week Phase 2 AMETHYST data showing continued efficacy, consistent safety for cutaneous lupus drug litifilimab

  • Phase 3 litifilimab results in cutaneous lupus expected in the first half of 2027.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)